[ad_1]
Among all the medical challenges that scientists have faced, Alzheimer’s disease, the most common form of dementia, is the most difficult. Between 1995 and 2021, private funds spent on Alzheimer’s research were a total of $ 42.5BN, but the over 140 testing failed to give a single medicine capable of slowing down the disease. Still the tide can change. There are two working drugs, which provide minor benefits in the market. A new review paper suggests that it may soon follow it.
There are 182 clinical trials for the treatment of Alzheimer’s in 2025 – 11% increase in the previous year – a list of 138 different drugs, 12 of which are ready to complete their final “phase 3” tests this year. In addition, this pipeline includes drugs aimed at a diverse range of goals in the brain, which reflects the rapidly sophisticated understanding of molecular processes behind Alzheimer’s and dementia.
For decades, the theory of Alzheimer’s research and domestic pipelines, known as amyloid hypothesis. It argues that the primary cause of the disease is the accumulation of plaques of beta-amyloid protein in the brain. It will be a waterfall of negative effects including neuronal dysfunction, brain-cell death and neuroinphone.
The amyloid hypothesis was supported by genetic evidence, showing mutation in major genes within families, which was linked to the early beginning of the disease. The success of two drugs is already treating Alzheimer’s -leakanmab and Donanmab, which came to the market in 2023 and 2024 respectively, respectively, it suggests that a connection exists. Both help to clean the amyloids from the brain, and provide slight help to a sate of patients for which the drug is considered safe and useful. According to clinical trials, they slow down the progression of the disease with about one third, which means that the patients can maintain the quality of their life for a long time.
The enthusiasm generated by these drugs was tingered, however, with the feeling that they were not much to show for decades of effort. Eccentric focus on amyloids was probably wrong. James Rowe, a professor at cognitive neurology at the University of Cambridge, says that although amiloid accumulation is an important “early trigger” for the disease, when patients arrive in their clinic, they are other nerve processes that expedite the disease. These include accumulation of the Mispen version of a protein called Tau; Increased metabolic stress on brain cells; Neuroinflamation; And collapse of brain blood supply.
A more fine understanding of Alzheimer’s is reflected in the development of the drug. It is the conclusion of Jeffrey Coming at Nevada University, Las Vegas University, and published in a review published on 3 June.
Academic experts, and investors, agree. Dame Kate Bingham is the managing partner of SV Health Investors, an enterprise-Put firm in London, which launched the first fund dedicated to the discovery of new remedies for dementia in 2015 in 2015. At that time the drug pipeline for Alzheimer’s focused on dealing with amylaids mainly. She says that the growing variety of possible goals gives her growing optimism today.
One-third of the new drugs are renovated completely, which means they are already approved for use in other conditions and Alzheimer’s is being rebuilt. The appeal to this approach is that drugs already have safety and toxicity profiles known, and it can be approved quickly and develop cheaply. One of the more famous is semaglutide, a diabetes and weight -loss drug whose anti -inflammatory and metabolic benefits have tested it as a treatment for mild cognitive loss. Meanwhile, the drug works on peromotine, melatonin and serotonin receptors in the brain, which helps to regulate sleep. As healthy sleep is considered to increase the rate on which amyloids and other waste proteins are cleaned, it can slow down the progress of Alzheimer’s.
Then the AR1001 (also known as Mirodenafil), which was originally developed for erectile dysfunction and is being tested for its neuroprotective properties. The drug increases the level of a molecule in the brain called CGMP, which, in turn, activates the routes that support the existence of nerve cells and improve connections between brain cells. This category of drugs are known to improve blood flow, so the drug can also have an effect on the vascular health of the brain.
Another renovated drug is nibbilon, which interacts with canbinoid receptors in the body. (The most famous molecule of this type is tetrahydrochainabinol, an active compound in cannabis). It was originally developed to treat nausea and vomiting in those under cancer chemotherapy. It is now being tested as a possible treatment for agitation and behavioral problems in those with Alzheimer’s. Guanfasin, a drug that improves attention and executive work in those with ADHD, is also being tested to see if it can provide similar benefits.
Received drugs are not necessarily more likely to success in late stages testing than people with a novel mechanism. Dame Kate argues that new approaches that use new molecular goals, rather than revival, will have the most impact on the disease.
An area of innovation centers around drugs that can deal with inflammation in the brain. Special attention is being paid to brain cells called microglia, which play a central role in the brain’s immune response and, possibly, its fight against Alzheimer’s fight. Micoglia is described as the fire fighting service of the brain, acting as police and binmen, as they respond to emergency conditions, maintain orders and clean the debris. Many drugs are trying to target protein trem2 on the surface of microglia in the hope of promoting their activity.
The combination of drugs is also being tested. For example, it is expected that a molecule obtained from plants, a cancer drug, and a pair of quercetin, will clean the aging and dysfunction cells. Drug combinations that target various routes and components of a disease, have created large inroads in other complex and surest diseases such as cancer and HIV.
Some errors of the past have been corrected. Dr. Rowe states that early attempts to designing amyloid-clearing drugs did not remove enough amyloids, or did so slowly. The selection of the patient was also poor in the tests, involved in many patients – which came out later – Alzheimer’s did not have absolutely.
Today’s tests still have blind spots, warning Antonella Santuchion-Chaha, the founder of the female brain Foundation, is a non-profit that studies how sex affects brain and mental health. She still fails to separate patients by sex, she says. Nevertheless, women are double the possibility of developing Alzheimer’s, a difference that cannot be explained only by their long lifetime, and the disease progresses differently in their brain. Dr. Chadha says, at any stage of the disease, tau proteins spread further in women than men.
This would help tests and patients – if more people were tested for the first of Alzheimer’s, so that they could be nominated to try new drugs. A single register of people with the disease will also be useful, making it easier for patients to find tests, and to find patients for pharmaceutical companies.
Therefore, therefore, is yet to be done. But for those who are a terrible and yet suffering from unbearable disease, who steal so many brains, there is some very important hope.
[ad_2]
